madman
Super Moderator
* Each speaker presented compelling arguments supporting different testosterone delivery systems, illustrating that no single therapy is universally ideal for every patient.
* Importantly, the session reinforced that the true “winner” of the debate was ultimately the patient. Rather than establishing a single superior testosterone formulation, the discussion emphasized the importance of individualized, patient-centered treatment selection tailored to each patient’s symptoms, lifestyle, comorbidities, treatment goals, and personal preferences. The speakers collectively highlighted that successful testosterone therapy requires balancing efficacy, safety, convenience, adherence, and quality-of-life outcomes while maintaining careful long-term monitoring.
At the Sunday afternoon plenary session, the Survivor Debate explored one of the most debated topics in men’s health and sexual medicine: the optimal approach to testosterone replacement therapy (TRT) for men with hypogonadism. Moderated by Abraham Morgentaler, the session featured four renowned experts who each defended a different testosterone delivery modality, including oral therapy, topical gels, injectable testosterone, and pellet therapy. The debate highlighted not only differences in efficacy and safety profiles, but also the growing importance of individualized treatment selection based on patient preference, convenience, adherence, cost, and long-term monitoring.
Oral Testosterone Therapy
Dr. Shindel presented the case for oral testosterone therapy, emphasizing the appeal of a noninvasive treatment option that avoids needles, topical application concerns, and office-based procedures. He discussed how newer oral testosterone formulations have expanded treatment options for men seeking a more convenient and discreet approach to TRT. Oral therapy was presented as particularly attractive for patients who prefer avoiding injections or daily topical application.
At the same time, Dr. Shindel acknowledged some of the practical limitations associated with oral testosterone formulations, including the need for multiple daily dosing schedules and administration requirements involving meals or dietary fat intake to optimize absorption. He also discussed the importance of careful patient selection and adherence when using oral agents. His overall argument emphasized how expanding therapeutic options allows clinicians to better tailor testosterone therapy to individual patient lifestyles and preferences.
Topical Testosterone Therapy
Dr. Khera strongly advocated for testosterone gels as the preferred TRT modality, arguing that topical testosterone currently has the strongest long-term safety data among all available testosterone formulations. He referenced findings from the Testosterone Trials and the TRAVERSE trial, emphasizing that testosterone gels were not associated with significant increases in prostate cancer, benign prostatic hyperplasia, myocardial infarction, stroke, or major cardiovascular events. He argued that these large safety studies provide particularly strong evidence supporting topical therapy.
A major component of Dr. Khera’s presentation focused on erythrocytosis and cardiovascular safety. He explained that injectable testosterone formulations often produce supraphysiologic testosterone peaks, which may contribute to higher rates of erythrocytosis and blood pressure elevation. In contrast, testosterone gels provide more stable testosterone levels with significantly lower erythrocytosis rates. He also highlighted observational data suggesting higher hospitalization and mortality rates associated with injectable testosterone compared with gel-based therapy.
Dr. Khera additionally emphasized the physiologic advantages of topical testosterone replacement, noting that gels more closely mimic natural circadian testosterone rhythms while minimizing large hormonal fluctuations. He argued that this helps reduce symptomatic cycling in mood, libido, and energy levels often seen with injections. Concerns regarding testosterone transfer were acknowledged, though he emphasized that clinically significant transfer events remain uncommon and largely preventable with proper counseling and hygiene practices. Overall, he concluded that testosterone gels offer the best combination of safety, efficacy, physiologic hormone delivery, and reversibility.
Injectable Testosterone Therapy
Dr. Hellstrom defended injectable testosterone therapy by focusing on its practicality, accessibility, and growing popularity in clinical practice. He began with a historical overview of testosterone therapy and the longstanding pursuit of rejuvenation and vitality throughout medical history. He then transitioned into the evolution of testosterone replacement and its broad systemic effects, including improvements in sexual function, energy, muscle mass, and overall quality of life.
Dr. Hellstrom emphasized that injectable testosterone remains one of the most commonly utilized TRT modalities because of its simplicity, affordability, and ease of administration. He discussed how newer autoinjector systems have helped reduce needle anxiety and improve patient comfort with self-administration at home. According to Dr. Hellstrom, injections provide predictable dosing intervals and avoid some of the adherence challenges associated with daily oral or topical therapies.
He also highlighted practical limitations associated with competing testosterone formulations. Oral and topical therapies were criticized for requiring multiple daily doses and strict administration schedules, while topical therapies continue to carry concerns regarding transference and insurance authorization barriers. Dr. Hellstrom further noted that newer testosterone products may not always be readily available at pharmacies and often require time-consuming insurance preauthorization processes.
Pellet Testosterone Therapy
Dr. Goldstein presented the argument for testosterone pellet therapy and emphasized the advantages of long-acting hormone delivery for appropriately selected patients. From a sexual medicine perspective, he highlighted the significant impact that testosterone deficiency can have on libido, sexual performance, mood, vitality, and overall quality of life. He argued that many patients value the convenience of long-duration testosterone replacement without the need for frequent injections, daily topical application, or multiple oral doses.
Dr. Goldstein discussed how pellet therapy may offer improved treatment adherence and stable testosterone levels over extended periods of time. However, he also acknowledged the procedural nature of pellet insertion, including the need for office-based implantation as well as risks such as discomfort, infection, and pellet extrusion. His presentation emphasized that despite these limitations, pellet therapy remains an attractive option for select patients who prioritize convenience and sustained testosterone delivery.
Overall, the debate highlighted the growing complexity and continued evolution of testosterone replacement therapy in modern urologic practice. Each speaker presented compelling arguments supporting different testosterone delivery systems, illustrating that no single therapy is universally ideal for every patient. Oral therapy emphasized convenience and noninvasive treatment, topical gels highlighted physiologic hormone delivery and strong safety data, injections focused on practicality and accessibility, while pellet therapy emphasized long-term convenience and sustained hormone replacement.
Importantly, the session reinforced that the true “winner” of the debate was ultimately the patient. Rather than establishing a single superior testosterone formulation, the discussion emphasized the importance of individualized, patient-centered treatment selection tailored to each patient’s symptoms, lifestyle, comorbidities, treatment goals, and personal preferences. The speakers collectively highlighted that successful testosterone therapy requires balancing efficacy, safety, convenience, adherence, and quality-of-life outcomes while maintaining careful long-term monitoring. Through contrasting perspectives from leaders in the field, the debate underscored how modern testosterone management continues to move toward increasingly personalized care in men’s health and sexual medicine.
* Importantly, the session reinforced that the true “winner” of the debate was ultimately the patient. Rather than establishing a single superior testosterone formulation, the discussion emphasized the importance of individualized, patient-centered treatment selection tailored to each patient’s symptoms, lifestyle, comorbidities, treatment goals, and personal preferences. The speakers collectively highlighted that successful testosterone therapy requires balancing efficacy, safety, convenience, adherence, and quality-of-life outcomes while maintaining careful long-term monitoring.
At the Sunday afternoon plenary session, the Survivor Debate explored one of the most debated topics in men’s health and sexual medicine: the optimal approach to testosterone replacement therapy (TRT) for men with hypogonadism. Moderated by Abraham Morgentaler, the session featured four renowned experts who each defended a different testosterone delivery modality, including oral therapy, topical gels, injectable testosterone, and pellet therapy. The debate highlighted not only differences in efficacy and safety profiles, but also the growing importance of individualized treatment selection based on patient preference, convenience, adherence, cost, and long-term monitoring.
Oral Testosterone Therapy
Dr. Shindel presented the case for oral testosterone therapy, emphasizing the appeal of a noninvasive treatment option that avoids needles, topical application concerns, and office-based procedures. He discussed how newer oral testosterone formulations have expanded treatment options for men seeking a more convenient and discreet approach to TRT. Oral therapy was presented as particularly attractive for patients who prefer avoiding injections or daily topical application.
At the same time, Dr. Shindel acknowledged some of the practical limitations associated with oral testosterone formulations, including the need for multiple daily dosing schedules and administration requirements involving meals or dietary fat intake to optimize absorption. He also discussed the importance of careful patient selection and adherence when using oral agents. His overall argument emphasized how expanding therapeutic options allows clinicians to better tailor testosterone therapy to individual patient lifestyles and preferences.
Topical Testosterone Therapy
Dr. Khera strongly advocated for testosterone gels as the preferred TRT modality, arguing that topical testosterone currently has the strongest long-term safety data among all available testosterone formulations. He referenced findings from the Testosterone Trials and the TRAVERSE trial, emphasizing that testosterone gels were not associated with significant increases in prostate cancer, benign prostatic hyperplasia, myocardial infarction, stroke, or major cardiovascular events. He argued that these large safety studies provide particularly strong evidence supporting topical therapy.
A major component of Dr. Khera’s presentation focused on erythrocytosis and cardiovascular safety. He explained that injectable testosterone formulations often produce supraphysiologic testosterone peaks, which may contribute to higher rates of erythrocytosis and blood pressure elevation. In contrast, testosterone gels provide more stable testosterone levels with significantly lower erythrocytosis rates. He also highlighted observational data suggesting higher hospitalization and mortality rates associated with injectable testosterone compared with gel-based therapy.
Dr. Khera additionally emphasized the physiologic advantages of topical testosterone replacement, noting that gels more closely mimic natural circadian testosterone rhythms while minimizing large hormonal fluctuations. He argued that this helps reduce symptomatic cycling in mood, libido, and energy levels often seen with injections. Concerns regarding testosterone transfer were acknowledged, though he emphasized that clinically significant transfer events remain uncommon and largely preventable with proper counseling and hygiene practices. Overall, he concluded that testosterone gels offer the best combination of safety, efficacy, physiologic hormone delivery, and reversibility.
Injectable Testosterone Therapy
Dr. Hellstrom defended injectable testosterone therapy by focusing on its practicality, accessibility, and growing popularity in clinical practice. He began with a historical overview of testosterone therapy and the longstanding pursuit of rejuvenation and vitality throughout medical history. He then transitioned into the evolution of testosterone replacement and its broad systemic effects, including improvements in sexual function, energy, muscle mass, and overall quality of life.
Dr. Hellstrom emphasized that injectable testosterone remains one of the most commonly utilized TRT modalities because of its simplicity, affordability, and ease of administration. He discussed how newer autoinjector systems have helped reduce needle anxiety and improve patient comfort with self-administration at home. According to Dr. Hellstrom, injections provide predictable dosing intervals and avoid some of the adherence challenges associated with daily oral or topical therapies.
He also highlighted practical limitations associated with competing testosterone formulations. Oral and topical therapies were criticized for requiring multiple daily doses and strict administration schedules, while topical therapies continue to carry concerns regarding transference and insurance authorization barriers. Dr. Hellstrom further noted that newer testosterone products may not always be readily available at pharmacies and often require time-consuming insurance preauthorization processes.
Pellet Testosterone Therapy
Dr. Goldstein presented the argument for testosterone pellet therapy and emphasized the advantages of long-acting hormone delivery for appropriately selected patients. From a sexual medicine perspective, he highlighted the significant impact that testosterone deficiency can have on libido, sexual performance, mood, vitality, and overall quality of life. He argued that many patients value the convenience of long-duration testosterone replacement without the need for frequent injections, daily topical application, or multiple oral doses.
Dr. Goldstein discussed how pellet therapy may offer improved treatment adherence and stable testosterone levels over extended periods of time. However, he also acknowledged the procedural nature of pellet insertion, including the need for office-based implantation as well as risks such as discomfort, infection, and pellet extrusion. His presentation emphasized that despite these limitations, pellet therapy remains an attractive option for select patients who prioritize convenience and sustained testosterone delivery.
Overall, the debate highlighted the growing complexity and continued evolution of testosterone replacement therapy in modern urologic practice. Each speaker presented compelling arguments supporting different testosterone delivery systems, illustrating that no single therapy is universally ideal for every patient. Oral therapy emphasized convenience and noninvasive treatment, topical gels highlighted physiologic hormone delivery and strong safety data, injections focused on practicality and accessibility, while pellet therapy emphasized long-term convenience and sustained hormone replacement.
Importantly, the session reinforced that the true “winner” of the debate was ultimately the patient. Rather than establishing a single superior testosterone formulation, the discussion emphasized the importance of individualized, patient-centered treatment selection tailored to each patient’s symptoms, lifestyle, comorbidities, treatment goals, and personal preferences. The speakers collectively highlighted that successful testosterone therapy requires balancing efficacy, safety, convenience, adherence, and quality-of-life outcomes while maintaining careful long-term monitoring. Through contrasting perspectives from leaders in the field, the debate underscored how modern testosterone management continues to move toward increasingly personalized care in men’s health and sexual medicine.
